- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Eikelboom Compares the COMPASS Trial to EUCLID and PEGASUS
Compared with the trial results of EUCLID and PEGASUS, the COMPASS trial advances the field of cardiovascular disease in combination therapies, said John Eikelboom, MD, of McMaster University.
Compared with the trial results of EUCLID and PEGASUS, the COMPASS trial advances the field of cardiovascular disease in combination therapies, said John Eikelboom, MD, of McMaster University.
Transcript (slightly modified)
Can you put the results of the COMPASS trial in perspective compared with the results of the EUCLID and PEGASUS trials?
The recent trials EUCLID and PEGASUS attempted to improve on the existing standard of care by evaluating alternative, more intensive, antithrombotic strategies. If we take EUCLID, this was a trial in patients with peripheral artery disease that evaluated ticagrelor as an alternative to clopidogrel. The EUCLID trial was very important, very large, a well-done study and it showed absolutely no benefit of ticagrelor. Thus, the EUCLID trial didn’t really advance treatment in peripheral artery disease.
The PEGASUS trial was an important, and, again, global, large, well-done study in patients post-myocardial infarction. In this trial, 2 doses of ticagrelor that were tested were on top of aspirin and the results indicate a reduction in major adverse cardiovascular events, an increase in bleeding, and no overall mortality benefit. So, in this context, the results of COMPASS really advanced the field because the combination therapy in COMPASS doesn’t only reduce major adverse cardiovascular events, but also reduces total mortality.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
